The market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...

Shares of Regeneron Pharmaceuticals Inc. REGN slid 1.35% to $564.64 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.07% to ...

When examining Regeneron Pharmaceuticals in comparison to its top 4 peers with respect to the Debt-to-Equity ratio, the following information becomes apparent: Regeneron Pharmaceuticals is in a ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Compare Credit Cards ... Regeneron has trounced the market over the trailing-12-month period, but it's essential to review these developments before buying the company's shares.

The study featured a head-to-head comparison between Pfizer's drug and Dupixent, which is marketed by Sanofi (SNY 0.12%) and Regeneron (REGN-3.69%). Could Pfizer beat Sanofi and Regeneron in the ...

Data & APIs. Events. Premarket ...

The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday Skip to main content ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a pharmaceutical company, which became of interest to me after a close friend tipped me off about their potential to enter the weight loss market ...

The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) net income didn't rise as precipitously, it did improve, gaining 2% to $1 ...

Regeneron (REGN) closed the most recent trading day at $595.73, moving +1.54% from the previous trading session. This change lagged the S&P 500's 2.76% gain on the day. Meanwhile, the Dow gained 2 ...